Choosing the right format is not about \u201cwhich is better.\u201d It is about what your process and program stage require.<\/p>\n\n\n\n
Fresh Leukopaks<\/a><\/h2>\n\n\n\n![\"\"](\"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-content\/uploads\/2.-leukopaks.png\")
<\/a><\/figure>\n\n\n\nBest for<\/h3>\n\n\n\n\n- workflows that process cells quickly after collection<\/li>\n\n\n\n
- programs prioritising maximum cell recovery and strong functional performance<\/li>\n\n\n\n
- teams optimising expansion kinetics or minimising stress factors<\/li>\n\n\n\n
- <\/a>early development when you want the cleanest read on your protocol<\/li>\n<\/ul>\n\n\n\n
Why choose fresh<\/h3>\n\n\n\n
Fresh leukopaks are often selected when you want to reduce variables. In general, they can offer strong cell recovery and a more direct view of donor biology without freeze-thaw effects.<\/p>\n\n\n\n
Fresh leukopaks are also useful when your workflow depends on high responsiveness to activation and expansion conditions.<\/p>\n\n\n\n
Considerations<\/h3>\n\n\n\n
Fresh material comes with scheduling and timing constraints. The value of a fresh leukopak depends heavily on:<\/p>\n\n\n\n
\n- time from collection to processing<\/li>\n\n\n\n
- temperature control in transit<\/li>\n\n\n\n
- consistency of collection and handling<\/li>\n<\/ul>\n\n\n\n
If those factors are not tightly managed, performance can vary.<\/p>\n\n\n\n
Summary<\/h3>\n\n\n\n\n- Average 15 billion TNC count<\/li>\n\n\n\n
- 10 billion cell guarantee<\/li>\n\n\n\n
- Available for immediate use<\/li>\n\n\n\n
- >99% average viability<\/li>\n\n\n\n
- Extensive USA coast-to-coast donor base<\/li>\n\n\n\n
- Customisable<\/li>\n<\/ul>\n\n\n\n
Cryopreserved Leukopaks<\/a><\/h2>\n\n\n\n![\"\"](\"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-content\/uploads\/cryo-leukopaks-1.png\")
<\/a><\/figure>\n\n\n\nBest for<\/h3>\n\n\n\n\n- programs needing predictable scheduling across sites<\/li>\n\n\n\n
- teams running repeated experiments or manufacturing runs using the same donor lots<\/li>\n\n\n\n
- workflows requiring inventory, long-term planning, or long-distance shipping<\/li>\n\n\n\n
- <\/a>development programs that want to lock in consistent starting material over time<\/li>\n<\/ul>\n\n\n\n
Why choose cryo<\/h3>\n\n\n\n
Cryopreserved leukopaks offer operational control. You can align runs to manufacturing availability, reduce last-minute scheduling issues, and maintain supply continuity.<\/p>\n\n\n\n
Cryo also supports repeatability. If your team needs the same donor material available for multiple timepoints, a cryopreserved supply makes that possible.<\/p>\n\n\n\n
Considerations<\/h3>\n\n\n\n
Cryopreservation introduces its own variables. Outcomes depend on:<\/p>\n\n\n\n
\n- freezing and storage methods<\/li>\n\n\n\n
- thaw technique<\/li>\n\n\n\n
- post-thaw recovery time<\/li>\n\n\n\n
- how your process handles freeze-thaw stress<\/li>\n<\/ul>\n\n\n\n
Some cell types recover better than others. That can subtly shift the immune composition after thaw and impact selection and expansion behaviour. If your process is highly sensitive, those shifts can show up as changes in yield, viability, and expansion kinetics.<\/p>\n\n\n\n
Summary<\/h3>\n\n\n\n\n- Always stocked in CGT’s cryo inventory and ready to order<\/li>\n\n\n\n
- 10 billion cell guarantee with overfill for each cryo leukopak<\/li>\n\n\n\n
- Short\/long term storage solutions<\/li>\n\n\n\n
- >96.33% average post thaw viability<\/li>\n\n\n\n
- Flexibility\/customisation<\/li>\n\n\n\n
- Worry-free shipping<\/li>\n<\/ul>\n\n\n\n
How fresh and cryo affect T cell enrichment and expansion<\/h2>\n\n\n\nEnrichment<\/h3>\n\n\n\n
If your goal is clean T cell isolation, both fresh and cryopreserved leukopaks can work, but the ease and consistency of selection often depend on how stable the post-thaw population is and how well your method tolerates debris and stressed cells.<\/p>\n\n\n\n
Expansion<\/h3>\n\n\n\n
Fresh material often supports strong responsiveness because cells have not been through freeze-thaw stress. Cryopreserved material can still expand well, but expansion curves may vary depending on post-thaw recovery and baseline donor biology.<\/p>\n\n\n\n
The key is aligning format selection with what your protocol expects.<\/p>\n\n\n\n
How to choose the right format for your program<\/h2>\n\n\n\nChoose fresh if:<\/h3>\n\n\n\n\n- you want to maximise performance and minimise variability introduced by freezing<\/li>\n\n\n\n
- you are optimising activation, transduction, and expansion conditions<\/li>\n\n\n\n
- you can control timing, shipping, and rapid processing<\/li>\n<\/ul>\n\n\n\n
Choose cryo if:<\/h3>\n\n\n\n\n- you need flexibility to schedule runs<\/li>\n\n\n\n
- you want consistent repeat access to the same donor material<\/li>\n\n\n\n
- you need inventory for multi-site work<\/li>\n\n\n\n
- your protocol has been validated to perform well post-thaw<\/li>\n<\/ul>\n\n\n\n
Many programs use both. Fresh in early development to understand baseline process behaviour, then cryo to support scaling and operational continuity.<\/p>\n\n\n\n
How to reduce variability with either format<\/h2>\n\n\n\n
Regardless of fresh or cryo, the biggest performance gains usually come from controlling three areas.<\/p>\n\n\n\n
\n- Collection protocol consistency<\/li>\n\n\n\n
- Donor screening aligned to program goals<\/li>\n\n\n\n
- Handling and logistics control<\/li>\n<\/ol>\n\n\n\n
If you are seeing inconsistent expansion, you can often trace it back to differences in immune composition, stressed cells, or variability in how collections and shipments were handled.<\/p>\n\n\n\n
How CGT Global supports fresh and cryopreserved leukopak supply<\/h2>\n\n\n\n
CGT Global<\/a><\/strong> supports both fresh and cryopreserved leukopak programs, so teams can choose the format that aligns with their manufacturing reality.<\/p>\n\n\n\nWe work with customers to align:<\/p>\n\n\n\n
\n- donor options and screening preferences<\/li>\n\n\n\n
- collection execution<\/li>\n\n\n\n
- handling and shipping requirements<\/li>\n\n\n\n
- supply format based on program stage<\/li>\n<\/ul>\n\n\n\n
If you are moving toward more repeatable manufacturing outcomes, tightening starting material inputs is one of the fastest and most controllable steps.<\/p>\n\n\n\n
Bottom line<\/h3>\n\n\n\n
Fresh and cryopreserved leukopaks can both support CAR T workflows. The right choice depends on whether you are optimising for maximum biological performance, operational flexibility, or repeatability.<\/p>\n\n\n\n
If you want help choosing the right format for your T cell enrichment and expansion process, CGT Global can help define starting material specs that match your workflow.<\/p>\n\n\n\n
\n\n\n\nOriginally posted by CGT Global on: https:\/\/cgt.global\/fresh-vs-cryopreserved-leukopaks-for-car-t-manufacturing\/<\/a><\/p>\n\n\n\nCaltag <\/a>is the distributor of these CGT Global<\/a> products in the UK and Ireland. If you have any questions about these products, please contact<\/a> us<\/a>.<\/p>\n\n\n\n<\/p>\n","protected":false},"excerpt":{"rendered":"
Both CGT’s fresh and cryopreserved leukopaks work well for CAR T, but the difference is what they optimise for. Here is a guide to help you choose the right one for you.<\/p>\n","protected":false},"author":13,"featured_media":12541,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16,1,964],"tags":[475,1055,878,798,967],"class_list":["post-12537","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blood-products","category-general-information","category-leukopak","tag-car-t","tag-cgt-global","tag-cryopreserved","tag-fresh","tag-leukopak"],"_links":{"self":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/12537","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/comments?post=12537"}],"version-history":[{"count":7,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/12537\/revisions"}],"predecessor-version":[{"id":12579,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/12537\/revisions\/12579"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/media\/12541"}],"wp:attachment":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/media?parent=12537"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/categories?post=12537"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/tags?post=12537"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
<\/a><\/figure>\n\n\n\nBest for<\/h3>\n\n\n\n\n- workflows that process cells quickly after collection<\/li>\n\n\n\n
- programs prioritising maximum cell recovery and strong functional performance<\/li>\n\n\n\n
- teams optimising expansion kinetics or minimising stress factors<\/li>\n\n\n\n
- <\/a>early development when you want the cleanest read on your protocol<\/li>\n<\/ul>\n\n\n\n
Why choose fresh<\/h3>\n\n\n\n
Fresh leukopaks are often selected when you want to reduce variables. In general, they can offer strong cell recovery and a more direct view of donor biology without freeze-thaw effects.<\/p>\n\n\n\n
Fresh leukopaks are also useful when your workflow depends on high responsiveness to activation and expansion conditions.<\/p>\n\n\n\n
Considerations<\/h3>\n\n\n\n
Fresh material comes with scheduling and timing constraints. The value of a fresh leukopak depends heavily on:<\/p>\n\n\n\n
\n- time from collection to processing<\/li>\n\n\n\n
- temperature control in transit<\/li>\n\n\n\n
- consistency of collection and handling<\/li>\n<\/ul>\n\n\n\n
If those factors are not tightly managed, performance can vary.<\/p>\n\n\n\n
Summary<\/h3>\n\n\n\n\n- Average 15 billion TNC count<\/li>\n\n\n\n
- 10 billion cell guarantee<\/li>\n\n\n\n
- Available for immediate use<\/li>\n\n\n\n
- >99% average viability<\/li>\n\n\n\n
- Extensive USA coast-to-coast donor base<\/li>\n\n\n\n
- Customisable<\/li>\n<\/ul>\n\n\n\n
Cryopreserved Leukopaks<\/a><\/h2>\n\n\n\n<\/a><\/figure>\n\n\n\nBest for<\/h3>\n\n\n\n\n- programs needing predictable scheduling across sites<\/li>\n\n\n\n
- teams running repeated experiments or manufacturing runs using the same donor lots<\/li>\n\n\n\n
- workflows requiring inventory, long-term planning, or long-distance shipping<\/li>\n\n\n\n
- <\/a>development programs that want to lock in consistent starting material over time<\/li>\n<\/ul>\n\n\n\n
Why choose cryo<\/h3>\n\n\n\n
Cryopreserved leukopaks offer operational control. You can align runs to manufacturing availability, reduce last-minute scheduling issues, and maintain supply continuity.<\/p>\n\n\n\n
Cryo also supports repeatability. If your team needs the same donor material available for multiple timepoints, a cryopreserved supply makes that possible.<\/p>\n\n\n\n
Considerations<\/h3>\n\n\n\n
Cryopreservation introduces its own variables. Outcomes depend on:<\/p>\n\n\n\n
\n- freezing and storage methods<\/li>\n\n\n\n
- thaw technique<\/li>\n\n\n\n
- post-thaw recovery time<\/li>\n\n\n\n
- how your process handles freeze-thaw stress<\/li>\n<\/ul>\n\n\n\n
Some cell types recover better than others. That can subtly shift the immune composition after thaw and impact selection and expansion behaviour. If your process is highly sensitive, those shifts can show up as changes in yield, viability, and expansion kinetics.<\/p>\n\n\n\n
Summary<\/h3>\n\n\n\n\n- Always stocked in CGT’s cryo inventory and ready to order<\/li>\n\n\n\n
- 10 billion cell guarantee with overfill for each cryo leukopak<\/li>\n\n\n\n
- Short\/long term storage solutions<\/li>\n\n\n\n
- >96.33% average post thaw viability<\/li>\n\n\n\n
- Flexibility\/customisation<\/li>\n\n\n\n
- Worry-free shipping<\/li>\n<\/ul>\n\n\n\n
How fresh and cryo affect T cell enrichment and expansion<\/h2>\n\n\n\nEnrichment<\/h3>\n\n\n\n
If your goal is clean T cell isolation, both fresh and cryopreserved leukopaks can work, but the ease and consistency of selection often depend on how stable the post-thaw population is and how well your method tolerates debris and stressed cells.<\/p>\n\n\n\n
Expansion<\/h3>\n\n\n\n
Fresh material often supports strong responsiveness because cells have not been through freeze-thaw stress. Cryopreserved material can still expand well, but expansion curves may vary depending on post-thaw recovery and baseline donor biology.<\/p>\n\n\n\n
The key is aligning format selection with what your protocol expects.<\/p>\n\n\n\n
How to choose the right format for your program<\/h2>\n\n\n\nChoose fresh if:<\/h3>\n\n\n\n\n- you want to maximise performance and minimise variability introduced by freezing<\/li>\n\n\n\n
- you are optimising activation, transduction, and expansion conditions<\/li>\n\n\n\n
- you can control timing, shipping, and rapid processing<\/li>\n<\/ul>\n\n\n\n
Choose cryo if:<\/h3>\n\n\n\n\n- you need flexibility to schedule runs<\/li>\n\n\n\n
- you want consistent repeat access to the same donor material<\/li>\n\n\n\n
- you need inventory for multi-site work<\/li>\n\n\n\n
- your protocol has been validated to perform well post-thaw<\/li>\n<\/ul>\n\n\n\n
Many programs use both. Fresh in early development to understand baseline process behaviour, then cryo to support scaling and operational continuity.<\/p>\n\n\n\n
How to reduce variability with either format<\/h2>\n\n\n\n
Regardless of fresh or cryo, the biggest performance gains usually come from controlling three areas.<\/p>\n\n\n\n
\n- Collection protocol consistency<\/li>\n\n\n\n
- Donor screening aligned to program goals<\/li>\n\n\n\n
- Handling and logistics control<\/li>\n<\/ol>\n\n\n\n
If you are seeing inconsistent expansion, you can often trace it back to differences in immune composition, stressed cells, or variability in how collections and shipments were handled.<\/p>\n\n\n\n
How CGT Global supports fresh and cryopreserved leukopak supply<\/h2>\n\n\n\n
CGT Global<\/a><\/strong> supports both fresh and cryopreserved leukopak programs, so teams can choose the format that aligns with their manufacturing reality.<\/p>\n\n\n\nWe work with customers to align:<\/p>\n\n\n\n
\n- donor options and screening preferences<\/li>\n\n\n\n
- collection execution<\/li>\n\n\n\n
- handling and shipping requirements<\/li>\n\n\n\n
- supply format based on program stage<\/li>\n<\/ul>\n\n\n\n
If you are moving toward more repeatable manufacturing outcomes, tightening starting material inputs is one of the fastest and most controllable steps.<\/p>\n\n\n\n
Bottom line<\/h3>\n\n\n\n
Fresh and cryopreserved leukopaks can both support CAR T workflows. The right choice depends on whether you are optimising for maximum biological performance, operational flexibility, or repeatability.<\/p>\n\n\n\n
If you want help choosing the right format for your T cell enrichment and expansion process, CGT Global can help define starting material specs that match your workflow.<\/p>\n\n\n\n
\n\n\n\nOriginally posted by CGT Global on: https:\/\/cgt.global\/fresh-vs-cryopreserved-leukopaks-for-car-t-manufacturing\/<\/a><\/p>\n\n\n\nCaltag <\/a>is the distributor of these CGT Global<\/a> products in the UK and Ireland. If you have any questions about these products, please contact<\/a> us<\/a>.<\/p>\n\n\n\n<\/p>\n","protected":false},"excerpt":{"rendered":"
Both CGT’s fresh and cryopreserved leukopaks work well for CAR T, but the difference is what they optimise for. Here is a guide to help you choose the right one for you.<\/p>\n","protected":false},"author":13,"featured_media":12541,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16,1,964],"tags":[475,1055,878,798,967],"class_list":["post-12537","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blood-products","category-general-information","category-leukopak","tag-car-t","tag-cgt-global","tag-cryopreserved","tag-fresh","tag-leukopak"],"_links":{"self":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/12537","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/comments?post=12537"}],"version-history":[{"count":7,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/12537\/revisions"}],"predecessor-version":[{"id":12579,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/12537\/revisions\/12579"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/media\/12541"}],"wp:attachment":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/media?parent=12537"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/categories?post=12537"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/tags?post=12537"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Why choose fresh<\/h3>\n\n\n\n
Fresh leukopaks are often selected when you want to reduce variables. In general, they can offer strong cell recovery and a more direct view of donor biology without freeze-thaw effects.<\/p>\n\n\n\n
Fresh leukopaks are also useful when your workflow depends on high responsiveness to activation and expansion conditions.<\/p>\n\n\n\n
Considerations<\/h3>\n\n\n\n
Fresh material comes with scheduling and timing constraints. The value of a fresh leukopak depends heavily on:<\/p>\n\n\n\n
- \n
- time from collection to processing<\/li>\n\n\n\n
- temperature control in transit<\/li>\n\n\n\n
- consistency of collection and handling<\/li>\n<\/ul>\n\n\n\n
If those factors are not tightly managed, performance can vary.<\/p>\n\n\n\n
Summary<\/h3>\n\n\n\n
- \n
- Average 15 billion TNC count<\/li>\n\n\n\n
- 10 billion cell guarantee<\/li>\n\n\n\n
- Available for immediate use<\/li>\n\n\n\n
- >99% average viability<\/li>\n\n\n\n
- Extensive USA coast-to-coast donor base<\/li>\n\n\n\n
- Customisable<\/li>\n<\/ul>\n\n\n\n
Cryopreserved Leukopaks<\/a><\/h2>\n\n\n\n
<\/a><\/figure>\n\n\n\nBest for<\/h3>\n\n\n\n
- \n
- programs needing predictable scheduling across sites<\/li>\n\n\n\n
- teams running repeated experiments or manufacturing runs using the same donor lots<\/li>\n\n\n\n
- workflows requiring inventory, long-term planning, or long-distance shipping<\/li>\n\n\n\n
- <\/a>development programs that want to lock in consistent starting material over time<\/li>\n<\/ul>\n\n\n\n
Why choose cryo<\/h3>\n\n\n\n
Cryopreserved leukopaks offer operational control. You can align runs to manufacturing availability, reduce last-minute scheduling issues, and maintain supply continuity.<\/p>\n\n\n\n
Cryo also supports repeatability. If your team needs the same donor material available for multiple timepoints, a cryopreserved supply makes that possible.<\/p>\n\n\n\n
Considerations<\/h3>\n\n\n\n
Cryopreservation introduces its own variables. Outcomes depend on:<\/p>\n\n\n\n
- \n
- freezing and storage methods<\/li>\n\n\n\n
- thaw technique<\/li>\n\n\n\n
- post-thaw recovery time<\/li>\n\n\n\n
- how your process handles freeze-thaw stress<\/li>\n<\/ul>\n\n\n\n
Some cell types recover better than others. That can subtly shift the immune composition after thaw and impact selection and expansion behaviour. If your process is highly sensitive, those shifts can show up as changes in yield, viability, and expansion kinetics.<\/p>\n\n\n\n
Summary<\/h3>\n\n\n\n
- \n
- Always stocked in CGT’s cryo inventory and ready to order<\/li>\n\n\n\n
- 10 billion cell guarantee with overfill for each cryo leukopak<\/li>\n\n\n\n
- Short\/long term storage solutions<\/li>\n\n\n\n
- >96.33% average post thaw viability<\/li>\n\n\n\n
- Flexibility\/customisation<\/li>\n\n\n\n
- Worry-free shipping<\/li>\n<\/ul>\n\n\n\n
How fresh and cryo affect T cell enrichment and expansion<\/h2>\n\n\n\n
Enrichment<\/h3>\n\n\n\n
If your goal is clean T cell isolation, both fresh and cryopreserved leukopaks can work, but the ease and consistency of selection often depend on how stable the post-thaw population is and how well your method tolerates debris and stressed cells.<\/p>\n\n\n\n
Expansion<\/h3>\n\n\n\n
Fresh material often supports strong responsiveness because cells have not been through freeze-thaw stress. Cryopreserved material can still expand well, but expansion curves may vary depending on post-thaw recovery and baseline donor biology.<\/p>\n\n\n\n
The key is aligning format selection with what your protocol expects.<\/p>\n\n\n\n
How to choose the right format for your program<\/h2>\n\n\n\n
Choose fresh if:<\/h3>\n\n\n\n
- \n
- you want to maximise performance and minimise variability introduced by freezing<\/li>\n\n\n\n
- you are optimising activation, transduction, and expansion conditions<\/li>\n\n\n\n
- you can control timing, shipping, and rapid processing<\/li>\n<\/ul>\n\n\n\n
Choose cryo if:<\/h3>\n\n\n\n
- \n
- you need flexibility to schedule runs<\/li>\n\n\n\n
- you want consistent repeat access to the same donor material<\/li>\n\n\n\n
- you need inventory for multi-site work<\/li>\n\n\n\n
- your protocol has been validated to perform well post-thaw<\/li>\n<\/ul>\n\n\n\n
Many programs use both. Fresh in early development to understand baseline process behaviour, then cryo to support scaling and operational continuity.<\/p>\n\n\n\n
How to reduce variability with either format<\/h2>\n\n\n\n
Regardless of fresh or cryo, the biggest performance gains usually come from controlling three areas.<\/p>\n\n\n\n
- \n
- Collection protocol consistency<\/li>\n\n\n\n
- Donor screening aligned to program goals<\/li>\n\n\n\n
- Handling and logistics control<\/li>\n<\/ol>\n\n\n\n
If you are seeing inconsistent expansion, you can often trace it back to differences in immune composition, stressed cells, or variability in how collections and shipments were handled.<\/p>\n\n\n\n
How CGT Global supports fresh and cryopreserved leukopak supply<\/h2>\n\n\n\n
CGT Global<\/a><\/strong> supports both fresh and cryopreserved leukopak programs, so teams can choose the format that aligns with their manufacturing reality.<\/p>\n\n\n\n
We work with customers to align:<\/p>\n\n\n\n
- \n
- donor options and screening preferences<\/li>\n\n\n\n
- collection execution<\/li>\n\n\n\n
- handling and shipping requirements<\/li>\n\n\n\n
- supply format based on program stage<\/li>\n<\/ul>\n\n\n\n
If you are moving toward more repeatable manufacturing outcomes, tightening starting material inputs is one of the fastest and most controllable steps.<\/p>\n\n\n\n
Bottom line<\/h3>\n\n\n\n
Fresh and cryopreserved leukopaks can both support CAR T workflows. The right choice depends on whether you are optimising for maximum biological performance, operational flexibility, or repeatability.<\/p>\n\n\n\n
If you want help choosing the right format for your T cell enrichment and expansion process, CGT Global can help define starting material specs that match your workflow.<\/p>\n\n\n\n
\n\n\n\nOriginally posted by CGT Global on: https:\/\/cgt.global\/fresh-vs-cryopreserved-leukopaks-for-car-t-manufacturing\/<\/a><\/p>\n\n\n\n
Caltag <\/a>is the distributor of these CGT Global<\/a> products in the UK and Ireland. If you have any questions about these products, please contact<\/a> us<\/a>.<\/p>\n\n\n\n
<\/p>\n","protected":false},"excerpt":{"rendered":"
Both CGT’s fresh and cryopreserved leukopaks work well for CAR T, but the difference is what they optimise for. Here is a guide to help you choose the right one for you.<\/p>\n","protected":false},"author":13,"featured_media":12541,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16,1,964],"tags":[475,1055,878,798,967],"class_list":["post-12537","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blood-products","category-general-information","category-leukopak","tag-car-t","tag-cgt-global","tag-cryopreserved","tag-fresh","tag-leukopak"],"_links":{"self":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/12537","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/comments?post=12537"}],"version-history":[{"count":7,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/12537\/revisions"}],"predecessor-version":[{"id":12579,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/12537\/revisions\/12579"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/media\/12541"}],"wp:attachment":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/media?parent=12537"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/categories?post=12537"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/tags?post=12537"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
![<\/a>development programs that want to lock in consistent starting material over time<\/li>\n<\/ul>\n\n\n\nWhy choose cryo<\/h3>\n\n\n\nCryopreserved leukopaks offer operational control. You can align runs to manufacturing availability, reduce last-minute scheduling issues, and maintain supply continuity.<\/p>\n\n\n\nCryo also supports repeatability. If your team needs the same donor material available for multiple timepoints, a cryopreserved supply makes that possible.<\/p>\n\n\n\nConsiderations<\/h3>\n\n\n\nCryopreservation introduces its own variables. Outcomes depend on:<\/p>\n\n\n\n\nfreezing and storage methods<\/li>\n\n\n\nthaw technique<\/li>\n\n\n\npost-thaw recovery time<\/li>\n\n\n\nhow your process handles freeze-thaw stress<\/li>\n<\/ul>\n\n\n\nSome cell types recover better than others. That can subtly shift the immune composition after thaw and impact selection and expansion behaviour. If your process is highly sensitive, those shifts can show up as changes in yield, viability, and expansion kinetics.<\/p>\n\n\n\nSummary<\/h3>\n\n\n\n\nAlways stocked in CGT’s cryo inventory and ready to order<\/li>\n\n\n\n10 billion cell guarantee with overfill for each cryo leukopak<\/li>\n\n\n\nShort\/long term storage solutions<\/li>\n\n\n\n>96.33% average post thaw viability<\/li>\n\n\n\nFlexibility\/customisation<\/li>\n\n\n\nWorry-free shipping<\/li>\n<\/ul>\n\n\n\nHow fresh and cryo affect T cell enrichment and expansion<\/h2>\n\n\n\nEnrichment<\/h3>\n\n\n\nIf your goal is clean T cell isolation, both fresh and cryopreserved leukopaks can work, but the ease and consistency of selection often depend on how stable the post-thaw population is and how well your method tolerates debris and stressed cells.<\/p>\n\n\n\nExpansion<\/h3>\n\n\n\nFresh material often supports strong responsiveness because cells have not been through freeze-thaw stress. Cryopreserved material can still expand well, but expansion curves may vary depending on post-thaw recovery and baseline donor biology.<\/p>\n\n\n\nThe key is aligning format selection with what your protocol expects.<\/p>\n\n\n\nHow to choose the right format for your program<\/h2>\n\n\n\nChoose fresh if:<\/h3>\n\n\n\n\nyou want to maximise performance and minimise variability introduced by freezing<\/li>\n\n\n\nyou are optimising activation, transduction, and expansion conditions<\/li>\n\n\n\nyou can control timing, shipping, and rapid processing<\/li>\n<\/ul>\n\n\n\nChoose cryo if:<\/h3>\n\n\n\n\nyou need flexibility to schedule runs<\/li>\n\n\n\nyou want consistent repeat access to the same donor material<\/li>\n\n\n\nyou need inventory for multi-site work<\/li>\n\n\n\nyour protocol has been validated to perform well post-thaw<\/li>\n<\/ul>\n\n\n\nMany programs use both. Fresh in early development to understand baseline process behaviour, then cryo to support scaling and operational continuity.<\/p>\n\n\n\nHow to reduce variability with either format<\/h2>\n\n\n\nRegardless of fresh or cryo, the biggest performance gains usually come from controlling three areas.<\/p>\n\n\n\n\nCollection protocol consistency<\/li>\n\n\n\nDonor screening aligned to program goals<\/li>\n\n\n\nHandling and logistics control<\/li>\n<\/ol>\n\n\n\nIf you are seeing inconsistent expansion, you can often trace it back to differences in immune composition, stressed cells, or variability in how collections and shipments were handled.<\/p>\n\n\n\nHow CGT Global supports fresh and cryopreserved leukopak supply<\/h2>\n\n\n\nCGT Global<\/a><\/strong> supports both fresh and cryopreserved leukopak programs, so teams can choose the format that aligns with their manufacturing reality.<\/p>\n\n\n\nWe work with customers to align:<\/p>\n\n\n\n\ndonor options and screening preferences<\/li>\n\n\n\ncollection execution<\/li>\n\n\n\nhandling and shipping requirements<\/li>\n\n\n\nsupply format based on program stage<\/li>\n<\/ul>\n\n\n\nIf you are moving toward more repeatable manufacturing outcomes, tightening starting material inputs is one of the fastest and most controllable steps.<\/p>\n\n\n\nBottom line<\/h3>\n\n\n\nFresh and cryopreserved leukopaks can both support CAR T workflows. The right choice depends on whether you are optimising for maximum biological performance, operational flexibility, or repeatability.<\/p>\n\n\n\nIf you want help choosing the right format for your T cell enrichment and expansion process, CGT Global can help define starting material specs that match your workflow.<\/p>\n\n\n\n\n\n\n\nOriginally posted by CGT Global on: https:\/\/cgt.global\/fresh-vs-cryopreserved-leukopaks-for-car-t-manufacturing\/<\/a><\/p>\n\n\n\nCaltag <\/a>is the distributor of these CGT Global<\/a> products in the UK and Ireland. If you have any questions about these products, please contact<\/a> us<\/a>.<\/p>\n\n\n\n<\/p>\n","protected":false},"excerpt":{"rendered":"Both CGT’s fresh and cryopreserved leukopaks work well for CAR T, but the difference is what they optimise for. Here is a guide to help you choose the right one for you.<\/p>\n","protected":false},"author":13,"featured_media":12541,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16,1,964],"tags":[475,1055,878,798,967],"class_list":["post-12537","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blood-products","category-general-information","category-leukopak","tag-car-t","tag-cgt-global","tag-cryopreserved","tag-fresh","tag-leukopak"],"_links":{"self":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/12537","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/comments?post=12537"}],"version-history":[{"count":7,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/12537\/revisions"}],"predecessor-version":[{"id":12579,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/12537\/revisions\/12579"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/media\/12541"}],"wp:attachment":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/media?parent=12537"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/categories?post=12537"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/tags?post=12537"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}](\"https:\/\/cgt.global\/wp-content\/uploads\/2026\/01\/Cryo-leukopak.png\"){kind=link}